ABOUT NDEI

NDEI Mission Statement 

NDEI is a multi-component educational initiative that addresses issues spanning the diabetes continuum, from epidemiology and pathophysiology of the disease and its associated complications and comorbidities, to the therapeutic options for prevention and treatment. Since 1996, NDEI has partnered with preeminent thought leaders to provide a diverse anthology of evidence-based type 2 diabetes educational content that meaningfully accommodates the unique learning needs and clinical challenges of healthcare professionals.  

NDEI.org: Trusted Online Destination for Diabetes Education 

NDEI is uniquely poised to reach audiences through traditional and innovative educational venues—most notably its award-winning website, NDEI.org.  

NDEI.org is a premier destination for type 2 diabetes education that addresses knowledge and practice gaps among healthcare professionals with the goal of enhancing patient care. More than 47,000 HCP registered members enjoy premium content offerings and innovative formats, including a slide library featuring more than 1,500 downloadable slides; summaries of guidelines; on-demand programs, including case studies, expert webcasts, and newsletters; and patient education handouts and resources. Membership is free.  

Educational Objectives 

NDEI content focuses on type 2 diabetes pathophysiology, the rationale for early intervention with appropriate lifestyle and pharmacologic management to arrest disease progression, the role of pharmacologic agents alone and in combination for minimizing diabetes complications, and strategies to improve patient adherence.  

To address identified knowledge and practice gaps in these areas, NDEI delivers scientifically rigorous, evidence-based programs, curricula, and tools that enable practicing clinicians to:  

  • Review guidelines and clinical practice recommendations for the diagnosis and management of type 2 diabetes, with emphasis on strategies for attainment of A1C goals 
  • Describe the implications of suboptimal glucose control and poorly controlled diabetes 
  • Understand the rationale for early, aggressive intervention to prevent type 2 diabetes onset among individuals with prediabetes and complications associated with disease progression among those with frank type 2 diabetes 
  • Describe the mechanisms of action, efficacy, and safety of available and emerging pharmacologic agents for the management of type 2 diabetes 
  • Review the role of pharmacologic agents alone and in combination for the treatment and management of type 2 diabetes and its complications and/or comorbidities 
  • Recognize the importance of lifestyle modifications in the arsenal of treatment options toward preventing type 2 diabetes onset or arresting disease progression 
  • Identify strategies to minimize micro- and macrovascular risk in type 2 diabetes based on available evidence  
  • Review the cardiovascular disease risk inherent among individuals with type 2 diabetes, and identify strategies for risk prevention and therapy optimization based on best-available evidence, including guidelines and recommendations 
  • Discuss the potential impact on patient care of novel therapeutic approaches for type 2 diabetes based on new clinical trial data 

NDEI Content 

A seasoned Editorial staff of writers and editors with more than 25 years' combined experience in type 2 diabetes and cardiovascular disease is responsible for NDEI content. Our Editorial staff members are not medical or health professionals. We work closely with our Faculty Advisors to create clinically relevant, scientifically rigorous content that addresses knowledge and practice gaps unearthed during a comprehensive needs assessment. Our Advisors review core programs, particularly those programs that discuss treatment options or confer clinical practice guidance.

Danielle Gabriel, VP, Independent Educational Initiatives at Ashfield Healthcare Communications, oversees content development and publishing for NDEI.

 Faculty Advisors     
 Mayer B. Davidson, MD 

 Mayer B. Davidson, MD 

Professor of Medicine
Charles R. Drew University and David Geffen School of Medicine
  Department of Internal Medicine
  Division of Endocrinology
University of California, Los Angeles
Contract Physician
Martin Luther King Outpatient Center
Los Angeles, California

   Vivian A. Fonseca, MD 

 

Vivian A. Fonseca, MD 

Professor of Medicine and Pharmacology
Chief, Section of Endocrinology
Tulane University Medical Center
New Orleans, Louisiana

 

         
 Henry N. Ginsberg, MD  

Henry N. Ginsberg, MD 

Irving Professor of Medicine
College of Physicians and Surgeons of Columbia University
Director, Irving Center for Clinical Research
NewYork–Presbyterian Hospital
New York, New York

  Edward S Horton MD 

Edward S. Horton, MD 

Professor of Medicine
Harvard Medical School
Senior Investigator
Joslin Diabetes Center
Boston, Massachusetts

         
 Silvio E. Inzucchi, MD 

Silvio E. Inzucchi, MD 

Professor of Medicine
  Division of Endocrinology
Clinical Director
  Section of Endocrinology
Director
  Endocrinology and Metabolism Fellowship
Director, Yale Diabetes Center
Yale University School of Medicine
New Haven, Connecticut

   Frank Lavernia MD  

Frank Lavernia, MD 

Founder and Director,
  North Broward Diabetes Center
Pompano Beach, Florida

         
  Peragallo 

Virginia Peragallo-Dittko, RN, BC-ADM, CDE 

Professor of Medicine
SUNY Stony Brook School of Medicine
Executive Director
  Diabetes and Obesity Institute
Winthrop University Hospital
Mineola, New York

   Anne Peters 

Anne Peters, MD 

Professor of Medicine
  Division of Endocrinology
Keck School of Medicine
Director, USC Clinical Diabetes Programs
University of Southern California
Los Angeles, California

         
 James W. Reed, MD  

James W. Reed, MD 

Professor of Medicine
Chief of Endocrinology & Metabolism
  Division of Internal Medicine, Section of Endocrinology
Grady Memorial Hospital
Morehouse School of Medicine
Atlanta, Georgia

     

Emeritus Faculty 
     
  Thomas A. Buchanan, MD 

 Thomas A. Buchanan, MD 

Vice Dean for Research
Director, Southern California Clinical and Translational Science Institute
Co-Director, USC Diabetes and Obesity Institute
Chief, Division of Endocrinology and Diabetes
Keck School of Medicine
University of Southern California
Los Angeles, California

     
         

The information presented on NDEI.org is not intended to replace the advice of a healthcare professional, nor to replace—but rather to support—the relationship between the patient and the healthcare provider.  

NDEI.org is sponsored by Ashfield Healthcare Communications, Lyndhurst, NJ.